Recursion is a clinical-stage TechBio company decoding biology with an AI-native drug discovery platform. It fosters a bold, collaborative culture across offices in the US, UK, Canada, and beyond, focused on speed, integrity, and patient impact.
Define and drive asset strategy for small molecule clinical programs in oncology and immunology/inflammation, integrating competitive positioning and biomarker strategy.
Translate Recursion OS and ClinTech insights into strategic advantages, ensuring proprietary data and computational insights maximally enable drug discovery and development.
Partner with functional leaders across clinical development, BD, finance, and platform teams to align resource allocation with strategic conviction and impact.